Or Refractory B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Or Refractory B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma [Phase 1]
Phase I clinical trial evaluating CY-219 CAR-T cell therapy for relapsed/refractory B-cell lymphoma; not yet recruiting.
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma [Phase 4]
This document reports a Phase 4 clinical trial update for a secondary infusion of Relma-cel in relapsed or refractory B-cell lymphoma, curre…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.
-
CLINICAL_TRIALS research · 2024-06-27Clinical Trial Update: L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating L218CAR19 in relapsed or refractory B-cell lymphoma, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma [Phase 4]
Phase 4 clinical trial update for relmacabtagene autoleucel infusion in relapsed or refractory B-cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-01-26Clinical Trial Update: Dual Target CAR-T Cells in B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update for dual-target CAR-T cells in B-cell lymphoma is ongoing, with the sponsor listed and the status currentl…
-
CLINICAL_TRIALS trial_result · 2018-01-05Clinical Trial Update: CART-19 Cells for R/R B-cell Lymphoma [Phase 2, Phase 3]
Clinical trial update for CART-19 cells targeting Relapsed or Refractory B-cell Lymphoma, in Phase 2 and Phase 3.